| Literature DB >> 33641875 |
Ruben Mesa1, Jeanne Palmer2, Ryan Eckert3, Jennifer Huberty3.
Abstract
Myeloproliferative neoplasms include essential thrombocythemia, polycythemia vera, and myelofibrosis. They are characterized by abnormal myeloid proliferation. Patients suffer from debilitating constitutional symptoms and splenomegaly. There have been advances in understanding the impact on quality of life in myeloproliferative neoplasms. Owing to the chronicity of these diseases, symptoms are considered in response criteria for clinical trials. This review wills cover how quality of life is measured in patients with myeloproliferative neoplasm. We review the impact of treatment options, including JAK inhibitors, allogeneic stem cell transplantation, and medications in development. We discuss nonpharmacologic methods of improving symptoms and quality of life.Entities:
Keywords: Inflammation; Integrative medicine; Myeloproliferative neoplasm; Quality of life
Mesh:
Year: 2021 PMID: 33641875 DOI: 10.1016/j.hoc.2020.12.006
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722